Tc-99m Hynic Octreotide SPECT-MRI in Brain Metastasis of Thyroid Papillary–Insular Cancer

Gambini, Juan; Núñez, Miguel; Vila, Ricardo; Noble, J. G.; Alonso, Ómar

doi:10.1097/rlu.0b013e3181bed084

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 99m Tc-tektrotyd, an octreotide derivative was recently synthesized for diagnosis of tumors overexpressing somatostatin receptor subtype 2 and, to a lesser extent, subtypes 3 and 5. 5,8 In this case, 99m Tc-tektrotyd SPECT/MRI software fusion could detect the primary pancreatic head tumor that was not possible using diagnostic CT. Furthermore, 99m Tc-tektrotyd showed a high uptake in the primary tumor without any focal uptake in the multiple liver metastases, which indicates an overexpression of somatostatin receptors in the primary lesion, in opposite to liver metastases.…”

Section: Figurementioning

confidence: 92%

99mTc-Tektrotyd SPECT/MRI in the Diagnosis of a Gastroenteropancreatic Neuroendocrine Tumor

Zandieh

Gambini²,

Haller³

et al. 2012

Clinical Nuclear Medicine

View full text Add to dashboard Cite

99m Tc-tektrotyd is a recently developed tracer for imaging neuroendocrine tumors. We report the case of a patient with a history of prostate cancer and chronic lymphocytic leukemia, who presented with a liver biopsy showing leukemic infiltration associated with chromogranin and CDX2 positivity, suggestive of metastases from an intestinal neuroendocrine tumor.While diagnostic CT did not detect the primary tumor and showed only some liver metastases, 99m Tc-tektrotyd SPECT/MRI fusion identified a pancreatic head tumor and several liver metastases.This case illustrates the feasibility and clinical value of SPECT/MRI fusion using 99m Tc-tektrotyd in neuroendocrine tumor patients. Key Words: SPECT/MRI, SPECT/CT, 99m Tc-tektrotyd, neuroendocrine tumor (Clin Nucl Med 2012;37: e84 -e85) REFERENCES 1. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging. 2010;10:83-91. 2. Parisella MG, Chianelli M, D'alessandria C, et al. Clinical indications to the use of 99mTc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors. division (SIAPEC/ IAP). Gastroenteropancreatic neuroendocrine neoplasms: the histology report. Dig Liver Dis. 2011;43(suppl 4):356 -360. 4. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220 -226. 5. Gabriel M, Hausler F, Bale R, et al. Image fusion analysis of (99m)Tc-HYNICTyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging. 2005;32:1440 -1451. 6. Apostolova I, Riethdorf S, Buchert R, et al. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement. Ann Nucl Med. 2010;24:477-483. 7. Ruf J, Heuck F, Schiefer J, et al. Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010;91:101-109. 8. Gambini JP, Núñez M, Vila R, et al. Tc-99m hynic octreotide SPECT-MRI in brain metastasis of thyroid papillary-insular cancer. Clin Nucl Med. 2009;34: 920 -921.

show abstract

Section: Figurementioning

confidence: 92%

99mTc-Tektrotyd SPECT/MRI in the Diagnosis of a Gastroenteropancreatic Neuroendocrine Tumor

Zandieh

Gambini²,

Haller³

et al. 2012

Clinical Nuclear Medicine

View full text Add to dashboard Cite

show abstract

Alternative Thyroid Imaging

Avram¹,

Rosenspire²,

Davidson³

et al. 2016

Thyroid Cancer

View full text Add to dashboard Cite

Detection of Recurrent Pancreatic Primitive Neuroectodermal Tumor by Tc-99m Hydrazinonicotinyl-Tyr3-Octreotide Scan

Jing

Li²,

Chen³

et al. 2011

Clinical Nuclear Medicine

View full text Add to dashboard Cite

A 24-year-old asymptomatic female with a history of exophytic primitive neuroectodermal tumor in the uncinate process of the pancreas was evaluated by Tc-99m hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) imaging as a part of the routine check-up. The images revealed focally increased activity in the head of the pancreas, indicating possible recurrent tumor. However, the results of all examinations considered, especially because of negative results from anatomic imaging, the finding from the HYNIC-TOC scan was regarded as likely false positive, and no new actions were taken. Eighteen months later, the patient developed abdominal mass. Repeat HYNIC-TOC imaging redemonstrated the focus of abnormal activity, which was confirmed as recurrent primitive neuroectodermal tumor pathologically.

show abstract

Tc-99m Hynic Octreotide SPECT-MRI in Brain Metastasis of Thyroid Papillary–Insular Cancer

Cited by 4 publications

References 5 publications

99mTc-Tektrotyd SPECT/MRI in the Diagnosis of a Gastroenteropancreatic Neuroendocrine Tumor

99mTc-Tektrotyd SPECT/MRI in the Diagnosis of a Gastroenteropancreatic Neuroendocrine Tumor

Alternative Thyroid Imaging

Detection of Recurrent Pancreatic Primitive Neuroectodermal Tumor by Tc-99m Hydrazinonicotinyl-Tyr3-Octreotide Scan

Contact Info

Product

Resources

About